Minimal hepatic encephalopathy (MHE) – influence of therapy with rifaximin on MHE and on the intestinal microbiome in patients with liver cirrhosis – the RiMINI-Trial - RiMINI

Trial Profile

Minimal hepatic encephalopathy (MHE) – influence of therapy with rifaximin on MHE and on the intestinal microbiome in patients with liver cirrhosis – the RiMINI-Trial - RiMINI

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Lactulose (Primary) ; Rifaximin (Primary)
  • Indications Hepatic encephalopathy; Liver cirrhosis
  • Focus Therapeutic Use
  • Acronyms RiMINI
  • Most Recent Events

    • 13 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top